<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098797</url>
  </required_header>
  <id_info>
    <org_study_id>SPIBA-201</org_study_id>
    <nct_id>NCT03098797</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome</brief_title>
  <acronym>TAZPOWER</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome Followed by an Open-Label Treatment Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blind cross over trial to evaluate the safety, efficacy and tolerability
      of elamipretide in subjects with Barth Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in distance walked during the 6-minute walk test (6MWT)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength as measured by handheld dynamometry</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in five times sit-to-stand test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-D and 3-D echocardiographic measurements</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in accelerometry counts</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SWAY application balance assessments</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcomes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician Global Impression</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Barth Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental: Elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elamipretide</intervention_name>
    <description>40 mg daily subcutaneous injection for 12 weeks</description>
    <arm_group_label>Experimental: Elamipretide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>MTP-131</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed Barth Syndrome

          -  Male aged 12 and above

          -  At the screening visit, eGFR must meet the following:

               1. Body weight &gt;30 kg AND eGFR &gt; 90mL/min at screening

               2. Body weight &gt;40kg AND eGFR &gt;60 but &lt;90mL/min at screening

          -  Ambulatory and impaired during the 6MWT

          -  On stable medication for 30 days prior to the baseline visit

        Exclusion Criteria:

          -  Participated in another interventional clinical trial within 30 days of or is
             currently enrolled in a non-interventional clinical trial at the baseline visit
             potentially confounding with this trial

          -  Prior or current medical condition that would prevent the subject from safely
             participating in the trial

          -  Undergone any inpatient hospitalizations within 30 days of the baseline visit

          -  Is undergoing an apparent pubertal growth spurt

          -  Has uncontrolled hypertension

          -  History of substance abused within the year before the baseline visit or is likely to
             be uncompliant

          -  History of heart transplantation or current placement on the waiting list for a heart
             transplant

          -  For subjects with an ICD: known occurrance of ICD discharge in the 3 months prior to
             the baseline visit

          -  For subjects without an ICD: expected to undergo an implantation of an ICD during the
             conduct of the study

          -  Currently receiving treatment with chemotherapeutic agents or immunosuppressant agents
             or has received prior radiation therapy to the chest

          -  Recipient of stem cell or gene therapy or is currently being treated by a therapeutic
             investigational device
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barth Syndrome</keyword>
  <keyword>elamipretide</keyword>
  <keyword>MTP-131</keyword>
  <keyword>Stealth</keyword>
  <keyword>Stealth BT</keyword>
  <keyword>BTHS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Barth Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

